BRIEF-AstraZeneca Says Nirsevimab Phase III Trial Met Primary Endpoint


Reuters | Moscow | Updated: 26-04-2021 12:06 IST | Created: 26-04-2021 11:56 IST
BRIEF-AstraZeneca Says Nirsevimab Phase III Trial Met Primary Endpoint
Representative Image Image Credit: ANI
  • Country:
  • Russian Federation

AstraZeneca PLC: * ASTRAZENECA PLC - NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT

* ASTRAZENECA PLC - NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT * ASTRAZENECA - FIRST POTENTIAL PASSIVE IMMUNISATION TO SHOW PROTECTION AGAINST RSV IN GENERAL INFANT POPULATION

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback